alfexe/iStock via Getty Images Akero Therapeutics, Inc. (NASDAQ:AKRO) has been able to report positive results from its phase 2b HARMONY study, which used its drug efruxifermin [EFX] for the treatment of patients with pre-cirrhotic MASH or Metabolic dysfunction-associated steatohepatitis with stage 2 or 3 fibrosis. The significance of this is that it is already in…
Daniel Christel/iStock via Getty Images Investment Overview Madrigal Pharmaceuticals (NASDAQ:MDGL), the Conshohocken, Pennsylvania based biotech, is the current leader of the “NASH Dash”, that is, the race to secure a first approval for a drug developed to treat nonalcoholic steatohepatitis, or “NASH” an advanced form of non-alcoholic fatty liver disease (“NAFLD”), where buildups of fat…
This article is featured in Bitcoin Magazine’s “The Primary Issue”. Click here to get your Annual Bitcoin Magazine Subscription. Click here to download a PDF of this article. “Economics I think is sort of like accounting — you know, it doesn’t immediately have any morals. You could go into welfare economics, you try to think…
ARMMY PICCA/iStock via Getty Images 89bio, Inc. (NASDAQ:ETNB) has made great progress in advancing its pipeline, especially since it has reached an agreement with regulators to advance two clinical studies using its drug pegozafermin to treat patients with NASH with compensated cirrhosis [F4] in the ENLIGHTEN-Cirrhosis study and then patients with Stages F2-F3 NASH in…